BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Healthtrust Education - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Healthtrust Education
X-ORIGINAL-URL:https://education.healthtrustpg.com
X-WR-CALDESC:Events for Healthtrust Education
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20190207T110000
DTEND;TZID=UTC:20190207T120000
DTSTAMP:20260407T111328
CREATED:20190103T201941Z
LAST-MODIFIED:20190103T202255Z
UID:10000188-1549537200-1549540800@education.healthtrustpg.com
SUMMARY:“Beyond SIRS—Rethinking Sepsis Screening in the Hospital”
DESCRIPTION:Saxe Healthcare Communications & Philips Healthcare* present…“Beyond SIRS—Rethinking Sepsis Screening in the Hospital” \n\n\n\n\nPLEASE Register Early. REGISTRATION ENDS 2 Hours BEFORE the start-time of the webinar broadcast.\n\n\n\n\nThis webinar will provide an overview of the burden of sepsis in the hospital and review the current recommendations for sepsis management. Various published tools for sepsis screening\, including SIRS and QSOFA\, and comparing their accuracy to one another and general early warning scores\, such as MEWS and NEWS will be discussed. Additionally\, there will be a review of the limitations regarding the subjective assessment of sepsis\, paying particular attention to whom is best situated to answer the question\, “Do you suspect infection?” The presenter will share research using big data analytics to improve detection and decrease the burden of sepsis screening in the hospital and demonstrate how that can be integrated into the electronic medical record. \nLearning Objectives  |  At the conclusion of this session\, the learner should be able to: \n\nDescribe the pros and cons of various sepsis screening approaches in the hospital\nDiscuss how big data and real-time analytics are transforming the sepsis screening landscape\n\nSpeaker: \n  \nDana Edelson\, M.D.\, MS  |  Assistant Professor of Medicine  |  University of Chicago Medicine \nContinuing Education for Nurses & Respiratory Therapists: This program has been approved for 1.0 contact hour of Continuing Education (CNE) credit by the California Board of Nursing\, Provider #14477 and the Florida Board of Nursing\, Provider #50-17032; and for 1.0 contact hour of Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care\, 9425 N. MacArthur Blvd.\, Suite 100\, Irving\, TX 75063. \nEducational support provided by Philips. \nQuestions should be directed to Emily Eberly at 513-579-0800; Producer@WebinarCreativeTechnology.com \n* NOTE: This is a supplier and industry resource-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products\, services\, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier\, product\, service\, drug\, brand or approach.
URL:https://education.healthtrustpg.com/calendar/beyond-sirs-rethinking-sepsis-screening-in-the-hospital/
CATEGORIES:Nursing,Respiratory
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20190207T120000
DTEND;TZID=UTC:20190207T133000
DTSTAMP:20260407T111328
CREATED:20190112T005245Z
LAST-MODIFIED:20190112T030424Z
UID:10000168-1549540800-1549546200@education.healthtrustpg.com
SUMMARY:“Consequences of FDA Changes to Critically Ill Bedside Glucose Testing Regulations”
DESCRIPTION:Nova Biomedical* presents… “Consequences of FDA Changes to Critically Ill Bedside Glucose Testing Regulations” \nPart I: Clinical Consequences  |  “Venous\, arterial\, and now capillary specimens are all FDA cleared for testing critically ill patients – Are all specimen types analytically and clinically equivalent?” \nThe choice of specimen type is an important consideration\, particularly for critically ill patients. This presentation will cover the analytical performance differences between different specimen types and their clinical significance. The data is based on the results of an FDA comparison study of 16\,778 paired patients test results. \nPart I Learning Objectives: \n\nAnalytical performance differences\nClinical significance of these differences\nSuggested best practice testing procedures\n\nPart I presenter: \n \nJeffrey A. DuBois\, Ph.D.  |  VP of Medical and Scientific Affairs  |  Nova Biomedical \n*             *             *             *             * \nPart II: Regulatory/Legal Consequences  |  “Regulatory requirements for off-label testing and the consequences of non-compliance”“ \nOne meter is FDA cleared and CLIA waived for use with all patients including critically ill. Use of all other meters with any critically ill patient population is considered off label by FDA and CMS. Hospitals cannot change the FDA’s off-label testing designations using their own testing or definitions. This presentation will review the history and rationale for recent FDA changes to bedside glucose testing in critically ill patients and the regulatory and legal consequences of off-label testing for caregivers and hospitals. \nPart II Learning Objectives: \n\nThe history and rationale for the FDA’s requirements for off-label bedside glucose testing from 2010 to 2018\nUnderstand when bedside glucose testing is off-label\nFDA testing requirements for off-label bedside glucose testing\nPatient risks if off-label testing is used for critically ill patients\nCaregiver’s personal liability risks when performing off-label glucose testing\nHospital liability risks when performing off-label glucose testing\nCLIA risks when performing off-label glucose testing\n\nPart II Presenter: \n \nNatalia Mazina\, Esq. |  Compliance Attorney |  FDA \nContinuing education credits |  Lab and Nursing  |  This program is accredited by the Society for Clinical Laboratory Science\, American Association of Critical Care Nurses\, American Society for Health Care Risk Management\, and ACCENT to offer a total of 1.00 CE credit (1.00 max). \nQuestions should be directed to Nova Biomedical: (781) 894-0800 |  info@novabiomedical.com \n* NOTE: This is a contracted supplier-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products\, services\, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier\, product\, service\, drug\, brand or approach.
URL:https://education.healthtrustpg.com/calendar/consequences-of-fda-changes-to-critically-ill-bedside-glucose-testing-regulations/
CATEGORIES:Lab,Nursing
END:VEVENT
END:VCALENDAR